Research on the anti-tumor mechanism of toosendanin combined with olaparib in triple negative breast cancer
- VernacularTitle:川楝素联合奥拉帕尼在三阴性乳腺癌中的抗肿瘤机制研究
- Author:
Huiqi HUANG
1
;
Qiuyuan WU
;
Kun ZHANG
;
Peixian LI
;
Yaming XIONG
;
Guolin YE
;
Dan ZHOU
Author Information
- Publication Type:Journal Article
- Keywords: triple negative breast neoplasms; toosendanin; autophagy; organoids; antineoplastic agents,phytogenic; olaparib; synergistic effect
- From: Tianjin Medical Journal 2025;53(9):897-903
- CountryChina
- Language:Chinese
- Abstract: Objective To investigate the anti-tumor mechanism of natural compound toosendanin(TSN)combined with olaparib in triple-negative breast cancer(TNBC).Methods Human TNBC cell line MDA-MB-231 was cultured in vitro.Effects of TSN combined with olaparib on autophagy levels and cell viability in MDA-MB-231 cells were evaluated using 0.5,1.0,and 5.0 μmol/L olaparib alone or in combination.Surgical specimens from four TNBC patients who had residual tumors after neoadjuvant chemotherapy were selected to establish patient-derived organoid(PDO)models.The drug sensitivity of TSN combined with olaparib in TNBC patients was detected.Whether TSN combined with olaparib can exert autophagy inhibitory effects and tumor-killing effects in organoid model was verified.Results Olaparib induced autophagy in MDA-MB-231 cell line,and the combination of TSN and olaparib inhibited the proliferation of MDA-MB-231 cells(P＜0.01).In the TNBC PDOs model,the therapeutic effect of olaparib combined with TSN can significantly reduce the proliferation ability of tumor cells compared with olaparib alone.Conclusion The tumor-killing effect of TSN combined with olaparib is superior to that of olaparib alone,and the mechanism may be related to autophagy inhibition.
